Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05650736 · ClinicalTrials.gov registry record · Phase 2
Janus Kinase Inhibition in Granuloma Annulare
A Phase 2 study of Granuloma Annulare, sponsored by William Damsky.
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05650736 is a Phase 2 study of Granuloma Annulare that is active but no longer recruiting, run by William Damsky. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05650736, a Phase 2 study of Granuloma Annulare, is active but no longer recruiting, sponsored by William Damsky.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to determine if JAK1 specific inhibition is effective in treating granuloma annulare (GA), a problematic inflammatory skin disease without an FDA approved treatment. The primary outcome will be the percentage change in the body surface area (BSA) involvement by GA after 6 months of treatment with abrocitinib 200 mg daily in 10 patients with moderate to severe GA affecting at least 5% body surface area (BSA).
Conditions Studied
Interventions
- DRUG Abrocitinib 200 mg
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-10-27 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05650736
The ClinicalTrials.gov registry entry for NCT05650736 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is William Damsky, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Granuloma Annulare appearing as the primary indexed condition, and to 1 intervention - of which Abrocitinib 200 mg is the first listed.
NCT05650736 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05650736 about?
NCT05650736 is a clinical study titled "Janus Kinase Inhibition in Granuloma Annulare". The primary objective is to determine if JAK1 specific inhibition is effective in treating granuloma annulare (GA), a problematic inflammatory skin disease without an FDA approved treatment. The primary outcome will be the percentage change in the body surface area (BSA) involvement by GA after 6 mo...
What is the current status of trial NCT05650736?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2023-10-27. Estimated completion is 2025-07-01.
What conditions does trial NCT05650736 study?
This clinical trial studies the following conditions: Granuloma Annulare.
What interventions are being tested in trial NCT05650736?
The interventions under investigation include: Abrocitinib 200 mg (DRUG).
Who is sponsoring clinical trial NCT05650736?
This trial is sponsored by William Damsky, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05650736 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.